Annual Trends in Medicare Part D Prescription Claims for Dupilumab 2017 to 2019.
J Drugs Dermatol
; 21(10): 1138-1139, 2022 Oct 01.
Article
en En
| MEDLINE
| ID: mdl-36219047
Disease control for moderate to severe atopic dermatitis (AD) has been primarily achieved with phototherapy and non-specific immunomodulators, cyclosporine, and methotrexate. These treatments have, however, been associated with many unfavorable side effects.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Dermatitis Atópica
/
Medicare Part D
Límite:
Aged
/
Humans
País/Región como asunto:
America do norte
Idioma:
En
Revista:
J Drugs Dermatol
Asunto de la revista:
DERMATOLOGIA
Año:
2022
Tipo del documento:
Article
Pais de publicación:
Estados Unidos